Welcome!
We are pleased to invite you to attend the 2018 Thrombosis Canada education conference, Advances in Thrombosis Management, 2018. The meeting will be held on Saturday, October 27, 2018 and features Canadian and international thrombosis experts. This program will cover a wide range of thrombosis-related topics relevant to your practice.
Accreditation
This program meets the accreditation criteria as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and has been accredited by the Office of Continuing Professional Development, Faculty of Medicine, McGill University for up to 5.5 Section 1 (Accredited Group Learning Activity) credits/hours. Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™.
Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
This Group Learning program meets the certification criteria of the College of Family Physicians of Canada and has been certified by the Office of Continuing Professional Development, Faculty of Medicine, McGill University for up to 5.5 Mainpro+ credits/hours. Physicians should claim only credit commensurate with the extent of their participation in the activity.
The Canadian Council on Continuing Education in Pharmacy has accredited this program for 12.5 CEUs.
Thrombosis Canada is seeking full accreditation for this educational program.
Target Audience:
Physicians, nurses and pharmacists involved in the management of patients with challenging medical or surgical conditions requiring personalized anticoagulant management.
Learning Objectives
After completing this program, you will be equipped to:
- Incorporate the latest evidence into the management of patients with thrombotic disease;
- Tailor evidence-based antithrombotic therapy in patients who require antiplatelet and anticoagulant therapies;
- Evaluate and implement the treatment of thrombosis in special populations. including obesity, kidney disease and thrombophilia;
- Support patients with cancer at risk of cancer-associated thrombosis and understand the role that therapeutic options play;
- Order appropriate diagnostic testing for DVT (deep vein thrombosis), including cancer screening and thrombophilia testing for confirmed DVT Apply insights from the conference to manage thrombosis challenges in clinical practice.
Please see the full agenda here: http://thrombosiscanada.ca/wp-content/uploads/2018/08/2018-Conference-Agenda-Aug-2018.pdf
